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This	 thesis	 is	 based	 on	 a	 randomised	 controlled	 trial	 comparing	 the	
effectiveness	 of	 intrauterine	 insemination	 (IUI)	 plus	 Controlled	 Ovarian	
Hyperstimulation	 (COH)	 versus	 in	 vitro	 fertilisation	 (IVF)	 as	 the	 first	 line	
treatment	option	for	couples	with	unexplained	subfertility.		
Subfertility	 of	 a	 couple	 is	 classed	 as	 unexplained	 when	 they	 fail	 to	
conceive	 after	 one	 year	 of	 regular	 unprotected	 intercourse	 and	 when	 all	 the	
standard	 investigations	 for	 ovulation,	 tubal	 patency	 and	 semen	 analysis	 have	
been	 found	to	be	normal.	 It	affects	30-40%	of	couples.	The	age-old	methods	of	
treating	 these	 couples	 have	 included	 the	 empirical	 use	 of	 clomiphene	 or	
gonadotrophins	 to	 correct	 any	 possible	 subtle	 defects	 in	 ovulation	 with	 or	
without	IUI	(to	overcome	any	existing	cervical	barrier	to	natural	conception)	or	
IVF.	 However,	 the	 best	 treatment	 options	 for	 these	 couples	 have	 yet	 to	 be	
determined.	The	matter	has	been	made	even	more	controversial	by	the	issue	of	
NICE	(National	Institute	for	Health	and	Care	Excellence)	guidelines	in	the	UK	that	
suggest	 IUI	be	abandoned	completely	 for	 these	women	 in	 favour	of	 IVF	after	2	
years	of	expectant	management.		
A	 systematic	 review	 of	 the	 available	 literature	 comparing	 IUI	 +	 COH	
versus	 IVF	 for	 unexplained	 subfertility	 revealed	 limited	 numbers	 of	 available	
studies	and	high	clinical	and	statistical	heterogeneity	among	them.	
An	 online	 survey	 was	 also	 conducted	 among	 fertility	 specialists	 to	
establish	 the	 general	 consensus	 regarding	 management	 of	 such	 couples.	 The	
results	 revealed	a	 lack	of	agreement	among	 fertility	 specialists	with	 regards	 to	




A	 randomised	 controlled	 trial	 was	 then	 designed	 to	 examine	 the	
effectiveness	 of	 COH	 with	 gonadotrophins	 +	 IUI	 versus	 IVF	 as	 the	 first	 line	
approach	 to	 the	 treatment	 of	 unexplained	 subfertility	 (Figure	 1).	 This	was	 the	
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This	 randomised	 controlled	 trial	 was	 initiated	 by	 drafting	 the	 research	
proposal	and	gaining	ethical	approval	for	the	research.	The	ethical	approval	was	
sought	 from	 Brent	 research	 ethics	 committee,	 ethical	 approval	 number	 being	
13/LO/0550.	Once	the	study	was	registered	(ISRCTN43430382),	the	process	of	
recruiting	patients	began	in	a	single	IVF	centre	catering	for	1200	cycles	per	year.	
Couples	 with	 female	 age	 between	 23-37	 completed	 years	 and	 diagnosed	 with	
unexplained	subfertility	at	 the	 time	of	 first	 treatment	were	deemed	eligible	 for	
the	trial.	They	were	randomised	to	either	3	cycles	of	COH	+	IUI	or	one	cycle	of	
IVF,	 to	be	completed	within	a	 time	horizon	of	6	months.	The	primary	outcome	





Though	 the	desired	 sample	 size	was	250,	only	207	patients	 could	be	 recruited	








group,	 while	 106	 couples	 were	 allocated	 to	 the	 IVF	 group.	 	 In	 the	 COH	 +	 IUI	























































































only	 in	 June	 2013	 that	 the	 recruitment	 process	 started	 and	 I	 enrolled	 for	 MD	 in	
October	2013.		The	recruitment	continued	for	two	years,	till	August	2015	and	then	I	
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(2016).	 ‘Unexplained	 subfertility:	 diagnosis	 and	 management’.	 The	 Obstetrician	
and	Gynaecologist,	18:	107-	15.	
Unexplained	subfertility	usually	refers	to	couples	who	fail	to	conceive	after	one	
year	of	 regular	unprotected	 sexual	 intercourse	 and	 in	whom	 investigations	 for	
ovulation,	tubal	patency	and	semen	analysis	have	been	found	to	be	normal1,	2.	It	






























of	 remaining	 oocytes	 and	 their	 quality9,	 the	 latter	 of	 which	 can	 lead	 to	 an	
increase	in	the	aneuploidy	rate	seen	in	the	embryos	from	older	women,	leading	
to	 non-implantation	 and	 subfertility 10 ,	 11 .	 A	 study	 by	 Maheshwari	 et	 al. 12	
demonstrated	 that	 women	 over	 35	 years	 of	 age	 were	 more	 likely	 to	 have	








uterine	 environment13.	 In	 men,	 it	 impairs	 the	 fertilising	 capacity	 of	 sperm	 by	
reducing	mitochondrial	activity	and	increasing	DNA	damage14.	Fortunately,	this	
damage	can	be	reversed	by	quitting	smoking15.		
Weight:	 Both	 obesity	 (BMI>30)	 and	 being	 underweight	 (BMI<19)	 can	 impair	






Alcohol:	 Excessive	 alcohol	 intake	 can	 cause	 subfertility.	 In	 men,	 even	 habitual	
drinking	 over	 5	 units	 per	 week	 has	 been	 found	 to	 have	 an	 adverse	 effect	 on	
sperm	 quality 21 .	 Alcohol	 consumption	 in	 women	 can	 reduce	 fertility	 by	
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decreasing	 the	 implantation	 rate,	 and	 by	 causing	 luteal	 phase	 dysfunction	 and	












the	 reproductive	 outcome,	 the	 ovarian	 reserve	 is	 limited	 to	 the	 prediction	 of	
ovarian	response	in	an	ART	cycle26.	Younger	women	with	a	low	ovarian	reserve	





Like	 tubal	 patency,	 the	 tubal	 function	 is	 also	 important	 to	 achieve	 successful	
pregnancy.	 Optimal	 tubal	 functions	 such	 as	 adequate	 ciliary	 motion	 and	
muscular	activity	are	required	for	sperm-oocyte	interaction	and	transport	of	the	
embryo	to	the	uterine	cavity	for	implantation28.	Milder	forms	of	gonorrhoea	and	
chlamydia	 infection	 can	 cause	 tubal	 function	 defect	 without	 causing	 overt	






possible	 cause	 for	 unexplained	 subfertility.	 Sperm	 defects	 such	 as	 abnormal	
acrosomes	 resulting	 in	 poor	 or	 no	 zona	 pellucida	 binding 30 	or	 defects	 in	
acrosome	reaction	resulting	in	failure	of	sperm-zona	pellucida	penetration,	have	
been	 proposed	 to	 be	 possible	 factors	 leading	 to	 subfertility31.	 Sperm	 DNA	
integrity	has	been	proposed	 to	be	 a	pre-requisite	 for	normal	 fertilisation32.	An	
otherwise	normal	semen	analysis	as	per	WHO	criteria	may	 include	sperm	with	
altered	genetic	material	caused	by	various	 factors	such	as	defects	 in	chromatin	
remodelling	 at	 the	 time	 of	 meiotic	 division,	 post	 testicular	 oxidative	 stress,	
various	environmental	factors	or	advanced	male	age32.	High	levels	of	sperm	DNA	





Structure	 Assay),	 single	 cell	 gel	 electrophoresis	 (COMET	 assay)	 and	 Terminal	





Undoubtedly	 a	 receptive	 endometrium	 is	 essential	 for	 successful	 implantation	








Dysregulation	 of	 the	 immune	 system	 and	 increased	 production	 of	 auto-	
antibodies	have	been	postulated	 to	be	 responsible	 for	unexplained	 subfertility.	
Autoimmune	 antibodies	 such	 as	 anti-thyroid,	 anti-ovarian,	 antinuclear,	
antiphospholipid	and	anti-smooth	muscle	antibodies	have	been	associated	with	
unexplained	 subfertility38.	While	 the	 exact	 role	 of	 these	 auto-antibodies	 in	 the	
pathogenesis	 of	 unexplained	 subfertility	 is	 unclear,	 various	 theories	have	been	
put	 forward,	 including	 reducing	 fertilisation	 rate,	 interfering	 with	 early	
implantation	 and	 modulating	 the	 function	 of	 FSH	 and	 thereby	 influencing	
ovarian	 function38, 39 .	 In	 addition	 to	 altered	 immune	 response,	 there	 are	
suggestions	 that	 thrombophilic	 gene	 polymorphism,	 such	 as	 the	 MTHFR	
(methylene	tetrahydrofolate	reductase)	gene	polymorphism,	could	be	a	cause	of	
unexplained	 subfertility40.	 Again,	 the	 possible	mechanism	 could	 be	 by	 causing	
early	 implantation	 failure;	however,	more	evidence	 is	needed	to	confirm	this41.	
Oxidative	stress	due	to	an	imbalance	between	reactive	oxygen	species	and	anti-
oxidants	 can	 be	 caused	 by	 various	 factors,	 including	 obesity,	 smoking,	 alcohol,	
recreational	drug	use	and	environmental	 exposure	 to	various	 toxins.	Oxidative	
stress	 has	 been	 linked	 with	 not	 only	 male	 subfertility	 by	 causing	 damaged	





diagnosed	 with	 mild	 endometriosis	 following	 laparoscopy44.	 The	 fecundity	 of	
women	 with	 mild	 endometriosis	 is	 similar	 to	 women	 with	 unexplained	
	 19	
subfertility45.	There	is	no	evidence	that	medical	treatment	of	mild	endometriosis	
improves	 fertility	 in	 these	 women.	 Moreover,	 laparoscopic	 ablation	 only	
improves	live	birth	rate	to	a	small	extent	46,47,48.	As	per	the	European	Society	of	
Human	 Reproduction	 and	 Society	 (ESHRE)	 guideline	 on	 management	 of	
endometriosis,	 for	 women	 with	 American	 Society	 of	 Reproductive	 Medicine	
(ASRM)	 stage	 I/II	 endometriosis,	 excision	 of	 endometriosis	 lesion,	 ovarian	
endometrioma	and	adhesiolysis	is	recommended	as	it	increases	the	spontaneous	





of	 fibroids	 could	 be	 associated	with	 reduced	 conception	 but	 evidence	 remains	
scarce49,	50.	 There	 is	 insufficient	 evidence	 that	 myomectomy	 for	 intramural	 or	
subserosal	 fibroids	 improves	pregnancy	 rates51.	The	 recent	ASRM	guideline	on	
treatment	of	myomas	in	asymptomatic	patients	to	improve	fertility	recommends	
myomectomy	(laparoscopic	or	hysteroscopic)	for	cavity	distorting	myomas	only.	























they	might	 fail	 to	 diagnose	 ovulation	 if	 not	 performed	 at	 the	 right	 time	 of	 the	
menstrual	 cycle2,54.	 The	presence	of	 a	 regular	menstrual	 cycle	 in	 itself	 is	 a	 fair	
























Assessment	 of	 tubal	 patency	 can	 be	 achieved	 by	 various	 methods	 such	 as	
hysterosalpingogram	 (HSG),	 hystero-contrast	 sonosalpingography	 (HyCoSy),	





WHO	 (World	 Health	 Organisation)	 criteria	 for	 semen	 analysis	 were	 released	



























follicle	 count,	 ovarian	 volume,	 clomiphene	 citrate	 challenge	 test,	 and	 the	
exogenous	FSH	ovarian	reserve	test58.	Though	basal	FSH	is	the	most	frequently	
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used,	 it	 presents	 significant	 intra-	 and	 inter-cycle	 variability,	 which	 limits	 its	
reliability.	 AMH	 on	 the	 other	 hand	 can	 be	 measured	 at	 any	 time	 during	 the	
menstrual	 cycle	 and	 both	 AMH	 and	 antral	 follicle	 count	 have	 good	 predictive	
value	 for	 response	 to	 ovarian	 stimulation59 .	 While	 these	 tests	 predict	 the	
response	 to	 ovarian	 stimulation	 during	 IVF,	 they	 are	 quite	 limited	 in	 their	
accuracy	to	predict	chances	of	spontaneous	conception60,61.	However,	according	
to	 the	American	College	of	Obstetricians	and	Gynaecologists	 it	 is	 reasonable	 to	
encourage	 a	 woman	 to	 attempt	 to	 conceive	 sooner	 rather	 than	 later	 if	 her	
ovarian	 reserve	 is	 found	 to	 be	 diminished,	 as	 her	 window	 of	 opportunity	 to	
conceive	might	be	shorter	than	anticipated62.	
1.2.5	Diagnostic	laparoscopy	
Women	with	 unexplained	 subfertility	with	 tubal	 patency	 confirmed	by	 normal	
HSG	 findings	 can	 still	 have	 peri-tubal	 adhesions	 and/or	 endometriosis,	 which	
can	lower	the	chances	of	their	spontaneous	conception63.	However	it	is	difficult	
to	predict	who	 is	going	 to	benefit	most	 from	 the	 surgery	and	 the	 concerns	are	
increased	 cost	 along	 with	 surgical	 risks	 and	 patient	 anxiety.	 Both	 ASRM	 (The	
American	Society	for	Reproductive	Medicine)	and	NICE	suggest	laparoscopy	only	
in	women	with	symptoms	of	comorbidities2,64.	In	2010,	Badawy	et	al	showed	in	a	
prospective	 randomised	 controlled	 trial	 that	 diagnostic	 laparoscopy	 could	 be	
postponed	 until	 3-6	 failed	 cycles	 of	 ovarian	 stimulation	 and	 timed	 sexual	
intercourse65.	While	 it	 is	 reasonable	 to	 postpone	 laparoscopy	 in	 asymptomatic	
women	with	normal	HSG	and	no	previous	history	of	pelvic	infection	or	surgery,	it	




Hysteroscopy	 is	 a	 reliable	way	 to	 diagnose	 and	 treat	 uterine	 cavity	 anomalies	
such	 as	 fibroids,	 polyps,	 septum	 and	 adhesions68.	 Women	 with	 unexplained	
subfertility	might	benefit	from	hysteroscopic	removal	of	submucous	fibroids	and	
polyps	 to	 improve	 their	 chances	 of	 conceiving50.	Where	 facilities	 are	 available,	
saline	 infusion	 sonography	 along	with	3-D	ultrasound	 can	offer	 a	 less	 invasive	






























They	 showed	 similar	 on-going	 pregnancy	 rates	 between	 the	 two	 groups	 (23%	
for	the	intervention	group	and	27%	for	the	expectant	management	group)70	and	




There	 are	 29	 such	 models.	 However	 they	 have	 been	 developed	 for	 different	









gynaecologists	 for	 over	 half	 a	 century.	 Various	 oil-soluble	 and	 water-soluble	
contrast	media	have	been	used	 for	HSG	and	have	been	 linked	to	an	 increase	 in	
the	chance	of	pregnancy.	The	 latest	Cochrane	review	summarised	 twelve	 trials	
involving	 2079	 participants	 and	 concluded	 that	 oil-soluble	 contrast	 media	






an	 effect	 on	 the	 endometrium	 to	 promote	 implantation76.	However,	 oil-soluble	
contrast	media	have	been	widely	replaced	by	water-soluble	contrast	media	due	






has	 been	 described	 in	 cases	 of	 oligo-ovulation,	 questions	 have	 been	 raised	










ovulation	 or	 slightly	 increase	 the	 number	 of	 oocytes	 available	 for	 fertilisation,	
thereby	 increasing	 the	 chances	of	 pregnancy80.	A	major	 concern	however	with	
multiple	follicle	development	in	IUI	+	COH	is	multiple	pregnancies81.	Using	mild	
ovarian	 hyper	 stimulation	 and	 strict	 cancellation	 policies,	 multiple	 pregnancy	
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rates	 can	 be	 kept	 to	 approximately	 10%	 without	 reducing	 pregnancy	 rates82.	
Two	studies	failed	to	show	any	benefit	of	IUI	with	or	without	COH	over	expectant	
management	 in	 terms	 of	 live	 birth	 rates	 in	 these	 couples70,77.	 Based	 on	 this	
evidence,	 NICE	 recommends	 not	 to	 routinely	 offer	 IUI	 for	 couples	 with	
unexplained	 subfertility	 but	 to	 proceed	 directly	 to	 IVF	 after	 two	 years	 of	
infertility.	 However,	 the	 success	 of	 IUI	 remains	 a	 controversial	 issue,	 as	 it	
depends	on	multiple	factors83.	Moreover,	a	recent	survey	of	fertility	clinicians	in	
the	 UK	 with	 a	 response	 rate	 of	 33%	 found	 that	 more	 than	 80%	 would	 still	
consider	IUI	+	COH	in	these	patients8.	
1.3.5	In	vitro	fertilization	(IVF)	
With	 advances	 in	 assisted	 reproductive	 techniques,	 IVF	 has	 emerged	 as	 a	 safe	
and	 successful	 treatment	 option.	 However,	 debate	 continues	 as	 to	 whether	 it	
should	be	the	sole	treatment	for	these	couples.		
The	 first	 randomised	 controlled	 trial	 by	 Goverde	 et	 al.	 (2000)84	compared	 six	
cycles	of	IUI	in	a	natural	cycle	versus	six	cycles	of	IUI	+	COH	versus	six	cycles	of	
IVF	 in	 258	 couples	 with	 unexplained	 subfertility	 and	 mild	 male	 factor.	 They	
found	that	though	the	pregnancy	rate	per	cycle	was	better	with	IVF	compared	to	
IUI	in	natural	cycle	or	IUI	+	COH	(12.2%	vs	7.45%	and	8.7%,	respectively),	there	
was	 no	 difference	 in	 the	 cumulative	 pregnancy	 rates	 (38%	 vs	 31%	 vs	 37%,	
respectively).	 However	 over	 the	 years	 pregnancy	 rates	 from	 IVF	 continued	 to	
improve	 and	 the	 current	 UK	 IVF	 success	 rates	 stand	 at	 27%-32%	 for	 women	
under	37	years	of	age	(HFEA.	Latest	UK	IVF	figures:	2010	and	2011).	One	might	
argue	that	the	pregnancy	rate	reported	by	Goverde	et	al.	is	out	of	date.	
Reindollar	 et	 al.	 (2010)85	showed	 in	 a	 large	 randomised	 controlled	 trial	 the	
effectiveness	 of	 moving	 to	 IVF	 after	 a	 course	 of	 clomiphene	 citrate	 and	 IUI	
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compared	to	conventional	treatments	of	clomiphene	citrate	and	IUI	and	FSH	and	
IUI	 and	 then	 IVF.	 In	 addition	 to	 achieving	higher	pregnancy	 rates,	 IVF	 allowed	





mild	 male	 factors	 and	 unfavourable	 prognosis	 of	 natural	 conception	 into	 two	
groups,	one	receiving	one	cycle	of	IVF-eSET	(elective	single	embryo	transfer)	and	
the	other	three	cycles	of	 IUI	+	COH.	 	They	showed	similar	 live	birth	rates,	with	
24%	in	the	IVF-eSET	group	and	21%	in	the	IUI	+	COH	group	(relative	ratio	1.17;	
95%	CI	0.60-2.30)	and	found	IUI	+	COH	to	be	more	cost	effective88.		
The	 most	 recent	 study	 by	 Bensdorp	 et	 al.	 (2015)89	sheds	 new	 light	 on	 the	
effectiveness	 of	 IUI	 and	 IVF	 for	 these	 couples.	 In	 this	multicentre	 randomised	
controlled	 trial	 involving	 17	 centres	 in	 The	 Netherlands,	 602	 couples	 with	
unexplained	 subfertility	 and	mild	male	 factors	 and	 unfavourable	 prognosis	 for	
natural	 conception	 were	 randomised	 into	 three	 groups,	 one	 receiving	 three	
cycles	 of	 IVF	 and	 single	 embryo	 transfer,	 the	 second	 six	 cycles	 of	 IVF	 in	 a	
modified	 natural	 cycle	 and	 the	 third	 receiving	 six	 cycles	 of	 IUI	 and	 COH.	 They	
found	comparable	singleton	live	birth	rates	(52%	vs	43%	vs	47%,	respectively)	
and	 comparable	 multiple	 pregnancy	 rates	 (6%	 vs	 5%	 vs	 7%,	 respectively)	
between	the	treatments.		
In	 2015,	 a	 Cochrane	 review	 summarised	 these	 trials	 and	 failed	 to	 prove	 the	
effectiveness	 of	 IVF	 over	 IUI	 with	 ovarian	 stimulation.	 They	 did	 not	 find	 any	




IUI	 is	 lower	 compared	 to	 IVF	 (9%	 vs	 22%)91,	 cumulative	 success	 rates	 are	
comparable	 to	 IVF89.	 From	 the	 couple’s	 perspective,	 IUI	 remains	 less	 invasive,	




In	 5%-25%	 of	 cases	 of	 unexplained	 subfertility,	 no	 fertilisation	 has	 been	
reported	 with	 conventional	 IVF	 procedures93 .	 This	 could	 be	 due	 to	 occult	
abnormalities	 in	 the	 sperm	 or	 oocyte94,	95.	 Intracytoplasmic	 sperm	 injection	
(ICSI)	 has	 been	 advocated	 for	 these	 couples96.	However,	 studies	 have	 failed	 to	
show	any	benefits	of	ICSI	over	IVF	in	terms	of	clinical	pregnancy	rates	(33%	IVF	
vs	 26%	 ICSI)97 	or	 live	 birth	 rates	 (46.7%	 IVF	 vs	 50%	 ICSI)98 .	 Recently,	 a	
systematic	 review	 summarized	 eleven	 studies	with	 a	 total	 of	 901	 couples	 and	
showed	a	higher	 fertilisation	 rate	with	 ICSI	 compared	 to	 IVF	 (RR	1.49,	95%	CI	
1.35-1.65)	 and	 the	need	 to	 treat	 five	 patients	with	 ICSI	 to	 prevent	 one	 case	 of	
fertilisation	failure99.	Due	to	paucity	of	data	they	could	not	analyse	the	pregnancy	
outcome	with	 ICSI	 in	 comparison	 to	 IVF.	 Neither	 NICE	 nor	 the	 ASRM	 practice	
committee	 recommend	 routine	 ICSI	 for	 unexplained	 subfertility	 2,	100.	However	
routine	 use	 of	 ICSI	 for	 at	 least	 some	 oocytes	 (split	 IVF-ICSI)	 offers	 several	




One	 of	 the	 important	 factors	 to	 consider	 is	 the	 cost	 of	 the	 treatments.	 The	
difficulty	in	performing	this	kind	of	analysis	is	due	to	the	differences	in	the	cost	
of	 treatment	 between	 different	 countries	 and	 between	 different	 regions	 in	 the	
same	country.	The	 study	by	Reindollar	 et	 al.	 (2010)85	 found	a	 saving	of	 $2624	
per	 couple	 in	 the	 immediate	 IVF	 arm	and	0.06	more	deliveries.	However,	 they	
analysed	 the	 cost	 according	 to	 the	 insurer’s	 charge	 data,	which	 could	 be	 quite	
different	from	the	cost	of	fertility	treatment	when	government-funded.	Likewise,	
the	 cost-effective	 analysis	by	Chambers	 et	 al.	 (2010)101	showed	 IVF	 to	be	 cost-
effective.	However,	this	study	can	be	criticised,	as	the	study	population	consisted	
of	patients	from	private	clinics	and	the	study	design	was	a	cohort	study.	Cohort	
studies	 being	 observational	 studies	 have	 inherent	 limitations	 of	 selection	 bias	
and	 unrecognized	 confounding	 factors,	which	might	 distort	 the	 results.	 On	 the	
contrary,	van	Rumste	et	al.88	showed	a	cost	saving	with	three	cycles	of	IUI	+	COH	
in	 comparison	 to	one	 cycle	of	 IVF-eSET	 in	 a	 randomised	 controlled	 trial	 in	 the	
Netherlands	 where	 fertility	 treatments	 are	 covered	 by	 healthcare	 insurance.	








choice	 among	 many	 women	 with	 unexplained	 subfertility,	 as	 it	 is	 less	 time-
consuming,	 cheaper	 and	 also	 less	 invasive.	 However,	 the	 treatments	 of	
unexplained	subfertility	have	always	been	a	matter	of	debate.	While	some	have	
questioned	 the	 use	 of	 agents	 to	 induce	 ovulation	 in	 women	 who	 are	 already	
ovulating102,	others	have	observed	 that	 the	use	of	 intrauterine	 insemination	 is	
only	 a	 modified	 substitute	 for	 natural	 intercourse70.	 New	 NICE	 guidelines	
suggest	 abandoning	 intrauterine	 insemination	 completely	 for	 these	women	 in	
favour	 of	 IVF	 after	 2	 years	 of	 expectant	 management2.	 Not	 many	 RCTs	 have	
been	conducted	to	compare	the	efficacy	of	IUI	and	ovarian	stimulation	to	IVF	in	
these	couples.	A	Cochrane	review	in	2012	(updated	in	2015)	has	admitted	that	
the	 effectiveness	 of	 IVF	 for	 unexplained	 subfertility	 relative	 to	 intrauterine	
insemination	remains	unproven90.	A	systematic	review	and	meta-analysis	of	the	
existing	 literature	was	 conducted	 to	 examine	 the	 effectiveness	 of	 IUI+COH	 vs	




Medline,	 Embase,	 CINAHL,	 PscyInfo,	 and	 Cochrane	 Library	were	 searched	 for	
relevant	 studies	 published	 between	 1980	 and	 May	 2015.	 A	 combination	 of	
medical	 subject	 headings	 (MeSH)	 and	 text	 words	 were	 used	 to	 generate	 two	
subsets	of	citations,	one	including	studies	on	IVF	(‘in	vitro	fertilization’,	‘in	vitro	
fertilisation’,	 ’fertilization	 in	 vitro’,	 IVF),	 IUI	 (‘insemination’,	 ‘insemination,	
artificial’,	 ‘insemination,	 artificial,	 homologous’,	 ‘intrauterine	 insemination’,	
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intrauterine	 insemination)	 and	 controlled	 ovarian	 stimulation	 or	 controlled	
ovarian	 hyperstimulation,	 and	 another	 including	 studies	 with	 unexplained	










Only	randomised	controlled	 trials	were	 included	without	 language	restrictions.	
The	review	was	restricted	to	published,	full-text	articles.		





Trials	 comparing	 IUI+COH	 (including	 controlled	 ovarian	 stimulation	 or	













34	 abstracts,	 which	were	 further	 reviewed	 to	 identify	 11	 eligible	 studies.	 Full	
texts	 of	 all	 11	 studies	were	 retrieved.	 Six	 fulfilled	 all	 the	 inclusion	 criteria	 and	






































All included studies were assessed for data extraction and quality assessment. Study 
characteristics, including study type, inclusion criteria, recruitment procedure, 
intervention, setting, and outcome measures, were extracted from each study 
(summarized in tables 5 and 6). All studies	 included were then assessed for trial 
quality following Cochrane guidelines109. Risks of bias in randomization sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective outcome reporting, and 
other areas were graded for all studies as low, high or unclear (table 7). Reasons for 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Zayed	et	al.	 Not	 true	 RCT.	 They	 described	 as	 pseudo	
randomisation,	 as	 a	 few	 couples	 who	 started	 as	 IVF	
were	 converted	 to	 intrauterine	 insemination	 due	 to	
under	 response	 and	 a	 few	 couples	 who	 started	 as	
intrauterine	 insemination	were	 converted	 to	 IVF	 due	
to	 over	 response	 and	 these	 were	 considered	 as	
treatment	changes	and	were	included	in	the	analyses.	
Also	 wishes	 of	 patients	 who	 wanted	 to	 change	 their	
allocated	treatment	were	respected.	




Compared	 super-ovulation	 alone,	 super-ovulation	
with	 intrauterine	 insemination,	 intra-peritoneal	









Tables	 5,	 6	 and	 7	 summarise	 the	 characteristics	 of	 the	 studies.	 Out	 of	 the	 six	
studies	included,	two	were	single-centre	trials84,103,	two	were	conducted	at	two-
centre85,	 86,	 and	 two	 were	 multi-centre	 trials87,89.	 Duration	 of	 subfertility	
considered	as	inclusion	criteria	by	various	studies	were	three	years84,	one	year	
85,87,89,103	and	six	months86.	Two	studies	included	cycles	using	donor	sperms87,89.	
Ages	 of	 the	 women	 included	 in	 different	 studies	 were	 ≤38	 only87,89,	 18-42	
years103,	 21-39	 years85	 and	 38-42	 years86,	 and	 in	 one	 study	 no	 age	 limit	 was	
specified84.		
2.3.4	Protocol	for	intrauterine	insemination	
For	 IUI	 cycles,	 some	 studies	 used	 75	 IU/day	 of	 FSH	 for	 ovarian	
hysperstimulation84,87,89	 ,	 some	 used	 112.5	 IU/day	 103,	 while	 others	 used	 150	
IU/day	of	FSH85	and	300IU	of	FSH86.	All	of	them	aimed	for	2-3-follicle	growths	for	
IUI	cycles.	Time	of	IUI	was	20-30	hours	after	urinary	LH	surge	and	40-42	hours	




another	 used	 100-150	 units	 recombinant	 rFSH87.	 A	 further	 study	 used	 a	 long	
agonist	protocol	 for	women	≤38	years	and	a	short	agonist	protocol	 for	women	
>38	 years	 with	 150-225	 units	 human	 menopausal	 gonadotrophins84,	 while	
another	used	 the	 same	protocol	 for	both	 IUI	 and	 IVF	using	112.5	 IU/day	 rFSH	
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starting	 from	 day	 3103.	 Another	 study	 used	 either	 a	 long/short	 agonist	 or	
antagonist	 protocol	with	 150	 IU	 FSH89,	 and	 one	 used	 a	 short	 agonist	 protocol	
starting	with	450	IU	of	human	menopausal	gonadotrophins86.	
Regarding	the	number	of	embryos	transferred,	Custers	et	al	(2011)	transferred	
one	 embryo	 on	 day	 3,	 or	 two	 embryos	 if	 no	 good	 quality	 embryos	 were	
available87;	 Elzeiny	 et	 al	 (2014)	 transferred	 one	 or	 two	 embryos	 at	 cleavage	
stage	(day	2-3)103;	Goverde	et	al	(2000)	transferred	a	maximum	of	2	embryos	on	
day	2-3	in	women	≤35	years,	and	3	embryos	in	women	>35	years84;	Reindollar	et	
al	 (2010);	 and	Goldman	 et	 al	 (2014)	 transferred	 embryos	 on	 day	 3	 (following	




In	 the	 study	 by	 Reindollar	 et	 al	 (2010)85	couples	 had	 previous	 treatment	with	
clomiphene	 with	 IUI	 up	 to	 three	 cycles	 before	 receiving	 IUI	 +	 FSH	 or	 IVF,	











et	 al	 (2000)84,	 reported	 cumulative	 pregnancy	 rates	 of	 IUI/IVF	 cycles.	 Only	
Bensdorp	 et	 al	 (2015)	 included	 healthy	 live	 birth	 as	 an	 outcome	 measure89;	





All	 six	 trials	 reported	 the	 live	 birth	 rate.	 In	 total,	 1183	 couples	were	 included,	
604	receiving	IUI	+	COH	and	579	receiving	IVF,	with	197	live	births	in	the	IUI	+	































unexplained	 subfertility	 (RR	 0.7,	 95%	 CI	 =	 0.61-0.81).	 However,	 this	 must	 be	
interpreted	with	caution,	as	the	number	of	studies	included	is	small	and	there	is	
very	high	heterogeneity	between	the	trials.	The	FASTT	(Fast	Track	and	Standard	
Treatment)	 trial	 by	 Reindollar	 et	 al.	 (2010)85	 showed	 no	 added	 benefit	 of	
gonadotrophin	 +	 IUI	 and	 shorter	 time	 to	 pregnancy	 with	 immediate	 IVF.	 It	
should	be	noted	that	all	women	in	this	trial	received	three	cycles	of	clomiphene	+	
IUI	 prior	 to	 receiving	 gonadotrophin	 +	 IUI	 or	 IVF.	 After	 three	 cycles	 of	
clomiphene	+	IUI,	a	good	proportion	of	women	who	were	to	achieve	pregnancy	
did	 so.	Hence,	 adding	 gonadotrophin	+	 IUI	 after	 clomiphene	 cycles	might	 have	
negatively	influenced	its	efficacy.	 	It	should	also	be	noted	that	in	the	immediate	
arm	of	the	trial,	patients	received	three	cycles	of	clomiphene	+	IUI	prior	to	IVF,	
making	 it	 questionable	whether	 this	 is	 immediate	 IVF	 in	 the	 truest	 sense.	 The	
FORT-T	 (Forty	 and	 over	 Treatment	 Trial)	 trial	 by	 Goldman	 et	 al.	 (2014)86	
included	 only	women	 aged	 38-42	 years.	With	 age	 there	 is	 a	 decline	 in	 oocyte	
numbers	 and	 quality,	 with	 an	 increase	 in	 the	 rate	 of	 aneuploidy,	 resulting	 in	
reduced	fecundity111.	Hence,	the	success	of	assisted	conception	in	general	is	low	
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in	 these	 women 112 .	 It	 would	 be	 unwise	 to	 extrapolate	 the	 outcome	 of	
gonadotrophin	+	IUI	in	these	women	to	younger	women.	
2.4.2	Multiple	pregnancy	rates	
One	 of	 the	main	 concerns	with	 ovarian	 stimulation	with	 gonadotrophin	 is	 the	
risk	 of	 multiple	 pregnancies.	 In	 our	 meta-analysis	 no	 significant	 difference	
between	 intrauterine	 insemination	 +	 gonadotrophins	 and	 IVF	 were	 noted	 in	
terms	 of	multiple	 pregnancy	 rates	 (RR	0.9,	 95%	CI	 0.53-1.53).	 In	 the	 study	 by	
Custers	et	al.	 (2011)87,	 there	were	2	 twin	pregnancies	 in	 the	 IVF	arm	and	both	
occurred	 after	 transfer	 of	 two	 fresh	 embryos	 of	 lower	 quality,	 whereas	 there	
were	3	multiple	pregnancies	(two	sets	of	twins	and	one	set	of	triplets)	in	the	IUI	
+	 gonadotrophin	 arm.	 The	 triplets	 occurred	 in	 an	 IUI	 cycle	 where	 there	were	
four	 follicles	 at	 the	 time	 of	 hCG	 administration.	 In	 the	 study	 by	 Goverde	 et	 al.	
(2000)84,	 they	 transferred	 up	 to	 two	 embryos	 in	women	 ≤35	 years	 and	 up	 to	
three	 embryos	 in	women	 >35	 years.	 There	were	 9	 pairs	 of	 twins	 in	 the	 IUI	 +	
gonadotrophin	arm	and	6	pairs	of	twins	and	one	set	of	triplets	in	the	IVF	group	
in	this	study.	In	the	study	by	Elzeiny	et	al	(2014)103,	there	was	no	case	of	multiple	
pregnancies	 in	 the	 IVF	 group	 and	 one	 twin	 pregnancy	 in	 the	 IUI	 group,	which	
miscarried	at	11	wks.	The	FORT-T	trial86	 transferred	day-3	embryos	as	per	the	
ASRM	 guideline110,	 which	 allows	 transfer	 of	 up	 to	 three	 day-3	 embryos	 for	
women	aged	38-40	years	and	up	to	 five	day-3	embryos	 for	women	aged	41-42	
year.	There	were	12	cases	of	multiple	pregnancies	 in	 this	 trial,	 one	 for	each	of	




order	births,	 including	one	set	of	 triplets	 in	the	IUI	arm	and	seven	twins	 in	the	
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IVF	arm.	They	were	strict	with	their	single	embryo	transfer	policy	regardless	of	
the	quality	 of	 embryo	 and	used	mild	 stimulation	during	 IUI.	It	 is	 quite	 evident	
that	 the	 stimulation	 policy	 during	 IUI	 and	 IVF	 and	 the	 number	 of	 embryos	




of	 gonadotrophins	 used	 and	 the	 number	 of	 follicles	 triggered	 with	 hCG80,113.	



















TTP	 four	months	after	 randomisation	between	 IVF	and	 IUI,	with	14	 live	births	
(24%)	 in	 the	 IVF	arm	and	12	(21%)	 live	births	 in	 the	 IUI	arm	(RR	1.2,	95%	CI	
0.6-2.3).	Similarly,	in	the	study	by	Bensdorp	et	al.	(2015)89,	the	TTP	for	IVF	and	
IUI	were	similar,	with	8.04	months	for	IVF	and	8.39	months	for	IUI. The	study	by	
Goldman	et	al.	 (2014)86	reported	a	TTP	of	3.0±0.1	months	 for	 two	cycles	of	 IUI	
and	5.7±0.2	months	after	immediate	IVF.	This	reflects	the	longer	time	it	takes	to	
prepare	for	and	complete	one	IVF	cycle.	On	the	contrary,	the	study	by	Reindollar	
et	 al.	 (2010)85	showed	 three	months	 of	 time	 saving	 by	 proceeding	 to	 IVF	 after	
clomiphene	+	IUI,	and	avoiding	FSH	+	IUI.	
2.4.5	Spontaneous	conceptions	
Couples	 with	 unexplained	 subfertility	 have	 a	 good	 prognosis	 for	 achieving	
spontaneous	conception7.	Hence,	 it	 is	worth	noting	 the	spontaneous	pregnancy	
rates	before	or	 in	between	 the	 treatment	cycles.	 In	 the	study	by	Goverde	et	al.	
(2000)84,	there	were	18	spontaneous	pregnancies	resulting	in	18	live	births	out	
of	 258	 participants	 (6.97%)	 and	 a	 delivery	 rate	 of	 1.25%	 per	 month	 for	
unexplained	 subfertility.	 Custers	 et	 al.	 (2011)87	 reported	 a	 spontaneous	
pregnancy	rate	of	3/116	(2.58%);	Reindollar	et	al.	(2010)85,	in	their	FASTT	trial,	
reported	 a	 rate	 of	 7/503	 (1.39%)	 for	 spontaneous	 pregnancy;	 Goldman	 et	 al.	
(2014)86	reported	14	(9.1%)	live	births	by	spontaneous	conception	before	or	in	
between	 treatments;	 and	Bensdorp	 et	 al.	 (2015)	 reported	 24/408	 (5.88%)	 for	
spontaneous	conception	for	the	IVF	and	IUI	+	COH	arm89.	In	the	study	by	Elzeiny	







the	American	studies	 found	 IVF	 to	be	more	cost	effective85,	86.	 In	 countries	 like	
America,	fertility	treatment	is	largely	self-funded,	whereas	in	European	countries	




that	 one	 cycle	 of	 IVF-eSET	 in	 their	 setting	would	 cost	 an	 additional	 €900	 per	












was	 112.0IU/day,	 which	 is	 higher	 than	 usually	 used	 throughout	 Europe	






0.06	 more	 deliveries.	 However,	 the	 cost	 they	 analysed	 is	 the	 insurer’s	 charge	
data,	 which	might	 be	 slightly	 different	 from	 the	 cost	 of	 providing	 the	 service.	
Again,	 they	 used	 an	 FSH	 dose	 of	 150	 IU/day	 for	 IUI,	which	 is	 higher	 than	 the	
usual	dose	across	Europe	(75IU/day).		
The	 interpretation	 of	 these	 figures	 is	 hindered	 by	 differences	 in	 the	 cost	 of	
treatment	between	different	countries	and	different	regions	in	the	same	country.	




live	 birth	 rate.	 However,	 this	 should	 be	 accepted	 with	 caution	 in	 view	 of	 the	
limited	 numbers	 of	 studies	 included	 and	 statistical	 heterogeneity	 that	 exists	
among	 them.	All	 the	 trials	 apart	 from	FORT-T	 trial	 included	 couples	with	mild	
male	 factors	 along	 with	 unexplained	 subfertility.	 Some	 trials	 included	 those	
using	donor	sperm	and	some	included	hypogonadotrophic	hypogonadism	along	
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3.1	Introduction	





+	COH	should	be	 considered	 carefully	 after	 evaluating	 its	 invasiveness	 and	 the	





among	 fertility	 specialists	 to	 establish	 the	 general	 consensus	 regarding	
management	of	these	couples.	
3.2	Method	
E-mail	 invitations	were	sent	 to	clinicians	who	were	UK	members	of	 the	British	
Fertility	 Society	 (BFS)	 to	 complete	 an	 online	 questionnaire	 on	 their	 usual	
practice	 while	 treating	 couples	 with	 unexplained	 infertility	 and	 their	 opinion	
regarding	 the	 new	 NICE	 proposal	 on	 this	 issue.	 The	 BFS	 list	 was	 used,	 as	 the	
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majority	of	fertility	specialists	in	the	UK	are	members.	Only	those	members	who	
made	 their	 email	 address	 available	 to	 other	 members	 were	 included	 in	 this	
survey.	 Out	 of	 454	 members	 in	 the	 member	 directory,	 420	 members	 were	
contacted	 via	 email.	 Options	 to	 opt	 out	 from	 this	 survey	were	 provided	 in	 the	
email	 invitation	and	all	 data	used	was	 anonymised.	Hence,	 no	 ethical	 approval	
was	 needed	 for	 this	 study	 (confirmed	with	 the	 local	 Research	&	Development	
department).	 The	 online	 questionnaire	 was	 set	 up	 using	 Survey	 Monkey	
(www.surveymonkey.com),	 an	 electronic	 data	 collection	 tool.	 There	 were	




































Q5:	 Do	 you	 consider	 stimulated	 IUI	 as	 a	 first	 line	 treatment	 option	 for	
these	patients?	
a.	Yes,	always		 	





a.	 Yes,	 always,	 irrespective	 of	 age	 and	
duration		
	




















With	 one	 person	 skipping	 the	 question,	 out	 of	 the	 remaining	 135,	 92	 (68.5%)	
were	 Consultants	 (Senior	 clinicians),	 15	 (11.11%)	 were	 Clinical	 Fellows	
(trainees	in	fertility),	12	(8.88%)	were	Associate	Specialists	(Senior	clinicians),	2	
(1.48%)	 were	 General	 Practitioner’s	 with	 special	 interest,	 3	 (2.22%)	 were	

















































a.	 Yes,	 always,	 irrespective	 of	 age	 and	
duration		
18	(16.07%)		























Following	one	 year	of	 unexplained	 infertility,	what	duration	of	 expectant	
management	 would	 you	 consider	 for	 these	 couples	 with	 unexplained	
infertility?	
106	out	of	136	respondents	answered	this	question.	While	the	majority	(95/106	


















it	 sometimes	and	17/109	(15.59%)	would	use	 it	 rarely.	The	majority	said	 they	
would	 use	 it	 depending	 on	 individual	 circumstances	 such	 as	 the	 couple’s	 age,	
ovarian	reserve	tests	(AMH,	antral	 follicular	count),	 funding	and	patient’s	wish.	
90/129	(69.76%)	would	consider	IUI	+	gonadotrophins	as	the	first	line	offer	for	
these	couples.	One	respondent	said	 that	 they	would	recommend	IUI	only	 if	 the	






IVF	 as	 a	 first	 line	 offer	 only	 if	 female	 age	 is	 >35	 years	 and/or	 duration	 of	
infertility	 is	 >2-3years.	 One	 respondent	 admitted	 that	 though	 they	 give	 the	









were	 unable	 to	 comment.	 Some	 admitted	 that	 there	 is	 a	 long	waiting	 time	 for	
NHS	 patients	 and	 believed	 that	 some	would	 conceive	 if	 offered	 stimulated	 IUI	
while	waiting	for	IVF.	









dilemma	among	practitioners	 regarding	 the	best	management	option	 for	 these	
couples.	While	 the	 majority	 (79/106)	 would	 offer	 6	 months	 to	 one	 year	 of	




50%	 of	 the	 respondents	 were	 in	 favour	 of	 using	 clomiphene	 citrate	 for	 these	
patients.	 Clomiphene	 citrate	 has	 been	 used	 for	 unexplained	 subfertility	 both	
alone	 and	 with	 IUI.	 One	 of	 its	 advantages	 is	 its	 low	 cost	 and	 ease	 of	
application120 ,121 .	 It	 is	 believed	 that	 it	 acts	 by	 correcting	 subtle	 ovulation	







cervical	 barrier,	 correct	 any	 subtle	 defect	 in	 ovulation	 or	 improve	 subtle	
undetected	sperm	imperfections.	It	has	long	been	quite	popular	among	patients	
with	unexplained	subfertility	with	 lower	dropout	rates	compared	to	IVF	due	to	
its	 less	 invasive	 and	 less	 time-consuming	 nature123.	 Success	 of	 IUI	 depends	 on	
many	factors,	including	total	washed	sperm	count124.	It	also	depends	on	the	unit	
offering	 IUI;	 according	 to	 some	of	 our	 respondents	 it	 is	 certainly	higher	 in	 the	
units	which	offer	IUI	only	rather	than	both	IUI	and	IVF.	Two	of	our	respondents	
claimed	 to	 achieve	 success	 rates	 of	 15-22%	 for	 IUI	 in	 their	 centres.	 IUI	 +	COH	
remains	popular	among	practitioners	as	evidenced	by	 this	 survey,	while	 IVF	 is	
not	yet	quite	popular	as	a	first	line	option	for	unexplained	subfertility.	
The	 2012	 NICE	 guidelines	 recommend	 offering	 IVF	 treatment	 to	 women	with	
unexplained	 subfertility	 after	 2	 years	 of	 expectant	 management	 with	 the	
exclusion	of	the	COH	+	IUI	option2.	However,	evidence	supporting	this	suggestion	
is	 limited.	 Even	 NICE	 has	 admitted	 that	 the	 evidence	 on	 which	 this	




money.	 Some	 supported	 IUI	 as	 they	 believed	 that	 IUI	 prepares	 the	 patient	
physically	and	psychologically	for	IVF.		
Bearing	 in	mind	 the	 reduced	 fecundity	 of	women	 over	 38	 years	 of	 age	 due	 to	
oocyte	 senescence,	 2	 years	 of	 expectant	 management	 might	 not	 be	 the	 right	





To	 the	best	 of	 our	 knowledge,	 this	was	 the	 first	 survey	 conducted	 to	 establish	
current	practice	in	the	UK	in	managing	women	with	unexplained	subfertility.	The	
diversity	 of	 responses	 received	 confirmed	 the	 variation	 in	 practices	 among	
reproductive	 specialists	 despite	 the	 existence	 of	 a	 National	 Guideline.	 It	 also	
confirmed	the	mixed	response	to	the	introduction	of	the	new	NICE	guideline	on	
unexplained	 subfertility	 and	 raised	 concern	 as	 to	 its	 wider	 acceptance,	 which	
seemed	to	be	blunted	by	the	lack	of	robust	evidence.		
3.5.2	Weaknesses	of	the	survey	
However,	 the	 survey	 had	 limitations.	 First	 of	 all,	 it	 was	 conducted	 among	
members	 of	 the	 British	 Fertility	 Society	 only;	 the	 policy	 of	 reproductive	
specialists	who	are	not	members	of	the	Society	could	therefore	not	be	assessed.	
However,	 a	 large	 section	of	 reproductive	 specialists	 in	 the	UK	 are	members	 of	
the	BFS.	The	return	rate	was	33%,	raising	concerns	 that	 it	might	not	be	a	 true	
representation	 of	 the	 overall	 practice;	 it	 did	 highlight	 the	 continued	 clinical	




The	 diversity	 in	 clinical	 practice	 in	 managing	 women	 with	 unexplained	
subfertility	 could	 be	 due	 to	 various	 reasons.	 The	 lack	 of	 robust	 evidence,	
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4.1	Introduction	
Debate	 continues	 as	 to	 whether	 IVF	 should	 be	 the	 sole	 treatment	 for	 couples	
with	unexplained	 subfertility.	Only	 a	 few	RCTs	have	 conducted	 a	head-to-head	
comparison	of	IUI	+	COH	and	IVF	in	unexplained	subfertility.	Currently,	there	is	a	





















• Couples	 with	 primary	 or	 secondary	 subfertility,	 of	 minimum	 one-year	
duration.	





21-35	 days	 and	 the	 mid-luteal	 serum	 progesterone	 level	 were	 used	 to	
confirm	ovulation.	
• Day	2	FSH	<10	IU/L.		
• Confirmed	bilateral	 patent	 tubes	were	 considered	 eligible.	Women	with	
unilateral	 blocked	 tube	 have	 some	 tubal	 factor	 already	 existing	 and	 the	




laparoscopy	 and	 dye	 test.	 HSG	was	 considered	 as	 a	 routine	 test	 for	 all.	
HyCoSy	 was	 considered	 if	 there	 were	 any	 suspicions	 of	 ovarian	 cysts	
and/or	 fibroids	 during	 examination	 or	 shown	 in	 previous	 scans.	 A	
laparoscopy	and	dye	test	was	considered	if	HSG/HyCoSy	were	equivocal	
or	 if	 the	 woman	 had	 any	 symptoms	 of	 pelvic	 pain,	 dysmenorrhea	 or	
dyspareunia	suggesting	possibility	of	endometriosis.		
• Mild	endometriosis	(American	Society	of	Reproductive	Medicine	(ASRM)	
grade	 I126,	 which	 has	 been	 previously	 surgically	 treated	 or	 patient	 is	
asymptomatic	were	included	in	the	trial48,127.		
• The	male	partner	with	normal	semen	parameters	 i.e.	sperm	density	>15	
million	 /ml,	 progressive	 motility	 >40%	 and	 normal	 forms	 >4%	 (WHO	






• Unilateral	 or	 bilateral	 blocked	 tubes.	 Women	 with	 previous	 ectopic	






on	 all	 participants	 and	 if	 uterine	 anomaly	was	 suspected	 in	 a	 3-D	 scan,	
then	hysteroscopy	was	performed	to	confirm	it.		
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• Couples	 with	 physical	 disability	 or	 psychosexual	 problems	 who	 had	
difficulty	in	achieving	vaginal	intercourse.	





• Those	 with	 confirmed	 endometriosis	 of	 Grade	 II-4	 (American	 Fertility	









catering	 for	 1200	 IVF	 cycles	 annually	 and	 serving	 couples	 from	 all	 ethnic	
background.	Patients	were	referred	by	their	General	Practitioner	or	 from	other	
hospitals.	Eligible	 couples	were	 identified	 from	 the	clinics	prospectively	on	 the	
basis	 that	 they	 fulfil	 the	 inclusion	 criteria.	 Written	 informed	 consent	 was	
obtained	before	randomisation	was	carried	out.	
4.2.4.2	Funding	









Once	 the	 patients	 had	 completed	 all	 relevant	 investigations,	 the	 chief	
investigator	 reviewed	 them.	 If	 patients	 met	 the	 inclusion	 criteria,	 they	 were	
verbally	 informed	about	 the	 trial	 and	were	 then	 given	 the	written	 information	
leaflet.	 They	were	 allowed	 and	 encouraged	 to	 read	 the	 information	 leaflet	 and	
given	a	further	follow	up	appointment	after	2-3	weeks.	
4.2.5.3	Agent	responsible	for	assigning	participants	to	interventions		
In	 the	 follow	up	visit,	 if	patients	expressed	 their	wish	 to	participate,	 they	were	
given	a	consent	form	to	sign.	Both	patient	and	her	partner	were	required	to	sign	
the	 consent	 form	 agreeing	 to	 participate	 in	 the	 trial.	 They	 were	 allowed	 to	
withdraw	 from	 the	 trial	 anytime	without	 any	 explanation	 and	without	 having	
any	effect	on	their	subsequent	treatment.	Once	the	consent	form	was	signed,	an	
independent	 research	 coordinator	 opened	 the	 sealed	 envelope	 to	 assign	 the	
couple	 to	 the	 intervention.	The	randomisation	number	along	with	 the	assigned	
intervention	was	documented	 in	 the	patient’s	notes	and	on	 the	 signed	consent	
form.	A	copy	of	the	consent	form	along	with	the	patient’s	details,	randomisation	
number	and	the	assigned	intervention	was	kept	in	the	research	file,	a	copy	was	
given	 to	 the	 patient	 and	 a	 copy	 was	 kept	 in	 the	 patient’s	 notes.	 A	 computer	





patients’	 notes	 at	 regular	 intervals	 of	 2-3	 months	 to	 correlate	 the	 received	
treatment	to	the	assigned	treatment	as	per	the	information	in	the	research	file.	
4.2.5.5.	Data	protection		
To	 protect	 patients’	 confidential	 information,	 the	 research	 file	 was	 kept	 in	 a	
secured	research	cabinet	in	an	NHS	hospital	and	was	monitored	by	the	research	
coordinator	of	the	unit.	It	was	always	kept	under	lock	and	key	and	was	accessible	
only	 in	 the	 presence	 of	 the	 research	 coordinator	 or	 unit	manager.	 The	 sealed	
envelopes	were	 kept	 in	 the	 research	 file.	 The	 Excel	 spreadsheet	with	 patients’	




A	 simple	 randomisation	 procedure	 was	 followed.	 A	 computerised	 random	
number	generator	was	used	to	generate	a	 list	of	random	numbers130,	assigning	
participants	to	one	of	the	two	treatment	groups	in	a	1:1	ratio,	and	distributed	in	
individual,	 consecutively	 numbered	 opaque	 envelopes.	 An	 independent	 person	
not	 involved	 in	 the	 trial	performed	 the	sequence	generation.	The	details	of	 the	
series	were	unknown	to	any	of	 the	 investigators	and	were	kept	away	 from	the	
hospital	to	be	inaccessible	to	the	investigators.	
4.2.6.2	Allocation	concealment	mechanism		




folded	 multiple	 times	 and	 kept	 inside	 the	 envelopes.	 The	 opaqueness	 of	 the	
envelopes	was	checked	by	two	independent	people	on	three	separate	occasions,	
in	random	batches	and	was	confirmed	against	intense	light	(sunlight,	light	bulb,	
X-ray	monitor).	 The	 research	 coordinator	 for	 the	 unit	 (not	 a	 part	 of	 the	 trial)	












A	 baseline	 scan	was	 performed	 between	 days	 2-5	 to	 exclude	 any	 ovarian	 cyst	
greater	than	2cm.	The	COH	was	performed	with	daily	subcutaneous	injections	of	
75	IU	FSH	(Fostimon,	a	highly	purified	urofollitropin,	Pharmasure)	starting	from	
day	 2-5	 of	 menstrual	 cycle	 onwards.	 The	 dose	 was	 altered	 according	 to	 the	
response	of	the	patient	and	was	decided	by	the	attending	clinician.	The	follicular	
growth	 was	 strictly	 monitored	 by	 transvaginal	 ultrasound.	 When	 at	 least	 1-2	
follicles	with	a	diameter	of	17-18mm	were	present,	final	oocyte	maturation	was	





were	 processed	 within	 one	 hour	 of	 ejaculation	 using	 density	 gradient	
centrifugation	 followed	 by	 washing	 with	 culture	 medium	 and	 then	 used	 for	
insemination.	 A	 single	 insemination	 was	 done	 by	 either	 the	 nurse	 or	 on-duty	
doctor133.		
4.2.7.2	IVF		
In	 the	 IVF	 group,	women	 underwent	 down-regulation	with	 GnRH	 agonist	 in	 a	
long	protocol,	starting	on	day	21	of	the	previous	cycle.	COH	was	started	with	FSH	
(either	 human	 menopausal	 gonadotrophins	 or	 recombinant	 FSH)	 with	 a	 dose	
ranging	from	150-450	IU	depending	on	the	woman’s	ovarian	reserve	(as	tested	
by	anti-Mullerian	Hormone	level,	basal	antral	follicle	count	and	day-2	FSH	level)	
and	 decided	 by	 the	 attending	 clinician.	 Follicular	 tracking	 was	 performed	 by	
transvaginal	 ultrasound.	 When	 the	 majority	 of	 the	 follicles	 were	 >18mm,	
ovulation	 was	 triggered	 with	 250mcg	 rhCG	 (Ovitrelle,	 Merck	 Serono)	 and	
cumulus-oocyte	 complexes	 were	 retrieved	 by	 transvaginal	 ultrasound-guided	
oocyte	 retrieval	 36	 hours	 after	 hCG	 trigger.	 ICSI	 (intra-cytoplasmic	 sperm	
injection)	was	 considered	 if	 <5million	 total	motile	 sperms	were	 available	 post	
wash.		
Women	who	were	deemed	high	risk	for	OHSS	(AMH>25,	AFC>20)	underwent	a	
GnRH	 antagonist	 protocol	 for	 stimulation,	 when	 COH	 was	 achieved	 with	 low	
dose	 FSH	 (150	 IU)	 and	 starting	 GnRH	 antagonist	 on	 day	 6	 of	 stimulation.	
Ovulation	was	 induced	by	GnRH	agonist	 (Buserelin,	 0.5	mg	 subcutaneously)134	
and	 oocyte	 retrieval	 was	 performed	 after	 36	 hours.	 If	 over	 20	 oocytes	 were	
collected,	 embryos	 were	 frozen	 and	 transferred	 at	 a	 later	 date	 in	 a	 frozen	
embryo	 replacement	 cycle.	 In	 that	 case,	 the	 first	 frozen	 embryo	 transfer	 cycle	
	 70	
was	 considered	 as	 first	 cycle	 and	 included	 in	 the	 analysis.	 Data	 for	 additional	
frozen	 embryo	 transfer	 cycles	were	 not	 collected,	 as	 this	was	 not	 in	 the	 study	
design.	
For	the	frozen	embryo	transfer	cycle,	down-regulation	was	achieved	with	GnRH	
agonist	 starting	 from	 day	 21	 of	 the	 previous	 cycle	 followed	 by	 endometrial	
preparation	 with	 daily	 estradiol	 valerate	 of	 8mg	 for	 10-14	 days	 or	 until	
endometrial	thickness	of	over	8mm	was	achieved.	
Embryos	 were	 assessed	 daily	 for	 morphological	 grading	 according	 to	 the	
laboratory’s	 protocol	 until	 the	 time	 of	 transfer.	 If	 one	 or	 more	 good	 quality	
embryos	were	available,	then	only	one	embryo	was	transferred	on	either	day	3	
or	 5.	 If	 no	 good	 quality	 embryos	 were	 available	 then	 two	 embryos	 were	
transferred.	 Luteal	 phase	 support	 was	 provided	 with	 progesterone	 vaginal	
pessaries	 (Cyclogest,	 400mg	 twice	 daily,	 Actavis	 UK	 Ltd).	 For	 frozen	 embryo	
transfer	 cycle	 or	 GnRH	 agonist	 trigger	 cycle,	 where	 a	 fresh	 embryo	 was	
transferred,	 daily	 estradiol	 valerate	 of	 8mg	 and	 progesterone	 gel	 (Crinone	 gel,	
Allergan)	 were	 given	 in	 addition	 to	 progesterone	 vaginal	 pessaries	 for	 luteal	
support.		
All	 procedures,	 follicular	 tracking	 scan,	 egg	 retrieval,	 embryo	 transfer	 and	 IUI	
were	performed	by	the	on	duty	doctor	(including	the	chief	investigator).	
4.2.8	Follow	up		
After	one	completed	cycle	of	COH	+	 IUI	or	 IVF,	 the	women	underwent	a	serum	
pregnancy	test	(serum	hCG)	at	2	weeks.	If	no	pregnancy	occurred	then	the	next	
treatment	cycle	was	started	as	per	the	protocol.	If	the	pregnancy	test	was	found	




If	 the	urine	 and	 serum	pregnancy	 test	were	positive	but	never	 reached	a	 level	
where	 an	 intrauterine	 pregnancy	 could	 be	 seen	 on	 ultrasound	 scan,	 it	 was	
classed	as	biochemical	pregnancy	and	considered	a	miscarriage.	
4.2.8.2	Clinical	Pregnancy	
If	 an	 intrauterine	 gestational	 sac	 with	 or	 without	 viable	 fetus	 was	 present	 on	
ultrasound	scan	then	it	was	classed	as	clinical	pregnancy.	
4.2.8.3	On-going	pregnancy		
If	 subsequent	ultrasound	scans	at	12	weeks	showed	a	viable	 intrauterine	 fetus	
then	 it	 was	 classified	 as	 an	 on-going	 pregnancy.	 Patients	 were	 registered	 for	
their	 antenatal	 care	 in	 their	 hospital	 of	 choice,	 which	 was	 noted	 for	 future	
correspondence.	
4.2.8.4	Ectopic	pregnancy	























Following	 the	 introduction	 of	 the	 2013	 NICE	 guideline,	 there	 was	 gradual	
withdrawal	 of	 NHS	 funding	 for	 IUI	 by	 most	 CCGs	 (Clinical	 Commissioning	
Groups).	As	this	trial	had	no	funding	and	patients	received	treatment	as	per	their	
NHS	 funding,	 the	 trial	 had	 to	 be	 stopped	 prematurely	 after	 recruiting	 207	
couples.		
4.2.11	Statistical	methods		
Differences	 in	 the	 birth	 rate	 per	 group	 were	 expressed	 as	 relative	 risks,	 with	
corresponding	 95%	 confidence	 intervals.	 This	 relative	 risk	 was	 unadjusted,	
following	 the	protocol	 and	analysis	plan	where	no	adjustment	 for	 confounders	
was	 specified.	 Data	were	 analysed	 as	 live	 singleton	 birth	 rates	 per	 couple.	 All	































































































































Between	 July	 2013	 and	 July	 2015,	 221	 couples	 diagnosed	 with	 unexplained	
subfertility	were	approached.	207	couples	agreed	to	participate	in	the	trial	and	
were	randomised	into	three	cycles	of	IUI	+	COH	(101)	and	one	cycle	of	IVF	(106).		
Overall,	 the	median	age	of	 the	 female	partner	was	32	years	 (IQR	30-35),	mean	
BMI	 23.6	 (SD	 3.01),	 median	 AMH	 19.6	 pmol/l	 (IQR	 10.9-31.3)	 and	mean	 AFC	
16.5	 (SD	 8.2).	 The	median	 duration	 of	 subfertility	was	 3	 years	 (IQR	 2-3).	 The	
mean	total	progressive	motile	sperm	count	was	52.4	(SD	11.4).		






















Out	 of	 101	 couples	 randomised	 to	 IUI	 +	 COH	 group,	 11	 patients	 did	 not	 start	
treatment	 either	 because	 they	 conceived	 spontaneously,	 or	 they	 had	 changed	
their	mind	regarding	starting	treatment	due	to	personal	or	medical	reasons.	90	
couples	 started	 their	 first	 cycle	 and	 69	 couples	 completed	 all	 three	 cycles.	 21	
couples	withdrew	after	one	or	two	cycles	of	IUI	and	underwent	18	cycles	of	IVF	
within	 the	 time	 frame	 for	 the	 trial.	 There	 were	 29	 live	 births	 (five	 were	
conceived	spontaneously	in	between	treatment	cycles	and	seven	from	IVF	cycles	
that	 patients	 underwent	 after	withdrawing	 from	 the	 IUI	 arm	 after	 one	 or	 two	
cycles	 of	 IUI)	 (29/101	 =	 28.7%	 per	 couple).	 There	 were	 three	 first	 trimester	
miscarriages	 and	 two	 ectopic	 pregnancies.	 There	 were	 four	 sets	 of	 twin	
pregnancies	(4/29	=	13.79%).	Two	were	conceived	from	IUI	and	two	from	IVF.	
The	per	couple	singleton	live	birth	rate	was	25/101	(24.7%).	
Out	of	101	 couples	 randomised	 to	 IUI	+	COH	group,	90	underwent	243	 cycles.	






produce	 sample	 on	 the	 day	 of	 IUI.	 Out	 of	 the	multiple	 pregnancies,	 two	were	
conceived	 from	 IUI	 cycles	 and	 both	 had	 two	 follicles	 during	 hCG	 trigger.	 The	






spontaneous	 conception,	withdrew	 from	 trial	 to	have	 IUI	or	did	not	undertake	
treatment	due	to	personal	circumstances	or	medical	reasons.	Out	of	 those	who	
underwent	 IUI,	 there	was	one	 live	birth.	As	per	 the	 intention	 to	 treat	 analysis,	
they	were	analysed	in	the	IVF	group.	81	couples	underwent	one	IVF	cycle.	
The	 mean	 dose	 of	 FSH	 used	 per	 cycle	 was	 3239.3	 ±	 1508.4	 IU	 for	 a	 mean	





OHSS	 cases	 had	 GnRH	 agonist	 trigger	 and	 freeze-all	 embryos.	 The	 mild	 OHSS	
case	had	hCG	trigger	in	an	antagonist	cycle.		
The	mean	number	of	oocytes	retrieved	per	cycle	was	13.2	±	6.9.	In	56	cycles	IVF	
was	used	 for	 fertilisation,	 in	 two	cycles	 ICSI	only	was	used	(due	 to	unexpected	
low	sperm	count	on	 the	day	of	oocyte	retrieval)	and	 in	23	cycles	both	 IVF	and	
ICSI	 (oocytes	 equally	 divided)	were	 used.	 There	were	 three	 cases	 of	 failure	 to	








blastocysts	 transferred	 and	 the	 other	 had	 two	 lower	 quality	 day-2	 embryos	














25	(24.7)	 33	(31.1)	 6.4%	(-5.8%-18.6%)	 1.3	(CI	0.8-1.9)	
Live	birth	rate	(per	
couple)	n	(%)	














3	(12.0)	 13	(26.5)	 	 2.2	(CI	0.6-7.0)	
Ectopic	pregnancy	
(n)	






5	(4.9)	 12	(11.3)	 	 	

























IUI	 group	 and	 one	 from	 those	 who	 withdrew	 from	 IVF	 and	 underwent	 IUI	
instead).	69	couples	in	the	IUI	group	completed	all	three	cycles	of	IUI	and	out	of	
three	couples	who	withdrew	from	IVF	group	and	had	IUI,	only	one	completed	all	
three	 cycles.	 Hence	 as	 per	 protocol,	 there	were	 18/70	 (25.7%)	 live	 births	 per	










































































0.69-7.05).	 The	 study	 dataset	 did	 not	 show	 an	 association	 between	 particular	
variables	and	miscarriage.		
In	view	of	 the	 large	number	of	 spontaneous	 conceptions,	which	 could	possibly	
obscure	 the	 effects	 of	 treatment	 regimes,	 a	 per	 protocol	 analysis	 was	 also	
performed.	While	one	cycle	of	IUI	seemed	to	be	associated	with	a	lower	success	
to	 that	of	 IVF	 in	 terms	of	 live	birth,	 three	cycles	of	 IUI	seemed	to	 lead	to	a	 live	
birth	almost	equal	to	that	of	one	cycle	of	IVF.		
4.4.1	Strengths	




of	 clomiphene	 citrate	 for	 unexplained	 fertility78;	 moreover,	 there	 is	 evidence	
suggesting	superiority	of	FSH	over	CC	when	used	in	conjunction	with	IUI136,137.			
Unlike	previous	studies,	which	 included	both	unexplained	subfertility	and	mild	
male	 factor	 subfertility84,	 87,	 89,	 this	 trial	 included	 couples	 with	 unexplained	
subfertility	only.	Couples	using	donor	sperm,	unlike	previous	studies87,	89,	were	
	 82	
excluded,	 as	 were	 women	 with	 hypothalamic	 anovulation	 or	 polycystic	 ovary	




oocyte	 senescence	 would	 reduce	 the	 success	 of	 IUI	 or	 IVF;	 there	 is	 recent	
evidence	 that	 reproductively	 older	 woman	 (≥38	 years)	 would	 benefit	 from	
immediate	IVF86.	
In	contrast	to	all	previous	trials,	which	included	women	with	a	unilateral	patent	
tube84,	85,	87,	89,	 this	 is	 the	 first	 trial	 to	 include	women	with	only	bilateral	patent	
tubes	 in	 HSG	 or	 laparoscopy.	 Women	 with	 unilateral	 blocked	 tube	 have	 an	
already	 existing	 tubal	 factor	 and	 evidence	 on	 the	 success	 of	 IUI	 +	 COH	 in	 this	
group	is	conflicting138,139,140.			
The	 main	 strength	 of	 this	 trial	 is	 its	 pragmatism,	 which	 increases	 the	
generalisability	of	the	findings.	Previous	trials	used	prognostic	models	to	select	a	
particular	groups	of	patients	to	be	included	in	their	trial87,	89.		There	are	over	29	
such	 prediction	 models	 developed	 for	 different	 patient	 profiles	 which	 can	 be	










again	 in	 contrast	 to	 previous	 trials	which	 aimed	 for	 2-3	 follicles	 and	 cancelled	
cycles	only	when	more	then	3	follicles	developed	87,	89.	There	was	mono-follicular	
growth	 in	70%	cases	 and	 still	 a	 live	birth	 rate	of	9%	per	 cycle	 and	25.7%	 live	
birth	 rate	per	 couple	 for	 three	 cycles	of	 IUI	+FSH	were	 achieved.	On	 the	other	
hand,	no	OHSS	was	encountered	and	there	was	a	multiple	pregnancy	rate	of	only	
9%	per	 live	birth.	This	 is	 in	agreement	with	the	randomised	controlled	trial	by	
Balasch	et	al.	(1994),	which	compared	75	units	of	FSH	with	50	mg	of	clomiphene	
for	ovulation	induction	in	IUI	cycles	in	couples	with	unexplained	subfertility	and	
showed	a	mono-follicular	 growth	of	 over	91%	and	on-going	pregnancy	 rate	 of	
13%	per	cycle	for	FSH	and	IUI142.	
To	 reduce	 the	 risk	 of	 multiple	 pregnancies,	 single	 embryo	 transfer	 was	
performed	 in	over	60%	of	 cases	 and	 the	multiple	pregnancy	 rates	 for	 IVF	was	
only	8%.		
There	 were	 17	 live	 births	 by	 spontaneous	 conception	 in	 between	 treatment	
cycles,	(17/207)	8.2%	per	couple.	These	couples	did	not	differ	significantly	from	
the	rest	of	the	cohort	in	their	baseline	characteristics	(Table	15).			








One	 of	 the	main	 limitations	 of	 this	 trial	 is	 that	 it	 had	 to	 be	 closed	 early	 after	
recruiting	207	 couples.	This	was	 a	purely	 administrative	decision	 and	was	not	
influenced	by	knowledge	of	the	results.		
	The	 obstetric	 and	 neonatal	 adverse	 outcomes	 associated	 with	 IUI/IVF	 cycles	
were	not	looked	at.	This	could	be	considered	as	one	of	the	limitations	of	this	trial.	
The	 cost	 analysis	 carried	out	here	 showed	 IUI	 to	be	 cost	 effective.	However,	 it	
should	be	interpreted	with	caution,	as	it	was	not	a	detailed	economic	evaluation.	
There	 is	no	national	 tariff	 for	 IUI	or	 IVF	 in	the	UK	and	the	cost	varies	between	
different	CCGs.	The	average	cost	 in	general	 is	around	£700	 for	one	cycle	of	 IUI	
and	£3200	for	one	cycle	of	IVF	under	the	NHS.	As	all	patients	who	participated	in	

















AFC	(mean	±	SD)	 17.8	±	7.9	 16.8	±	8.2	 0.63	






perform	 the	 cost	 analysis.	 I	 did	 not	 include	 additional	 frozen	 embryo	 transfer	




after	 failed	 cycles).	 It	would	 not	 have	 been	 possible	 to	 finish	 the	 trial,	 analyse	







relative	 nature	 of	 infertility	 in	 this	 patient	 population,	 reflected	 by	 the	 large	








with	 unexplained	 subfertility.	 The	 absence	 of	 a	 definitive	 cause	 for	 subfertility	
makes	the	treatment	 for	these	couples	empirical.	While	expectant	management	
is	 an	 effective	 option	 for	 some	 of	 them,	 clinicians	 come	 under	 considerable	
pressure	 from	 patients	 to	 provide	 a	 definitive	 management	 due	 to	 lack	 of	
confidence	 in	 natural	 conception.	 Various	 options	 such	 as	 using	 ovulation-
inducing	agents,	 intrauterine	 insemination	with	or	without	ovarian	stimulation	
and	 IVF	 have	 been	 proposed	 and	 used	 for	 these	 couples.	 However,	 not	 many	
trials	have	 compared	 these	 treatments	 and	 the	best	 first	 line	 treatment	option	
for	these	couples	remains	unsubstantiated.		
The	online	survey	performed	here	among	current	UK	fertility	specialists	clearly	
shows	 the	 on-going	 dilemma	 among	 the	 fertility	 experts’	 in	 managing	 these	
couples.	Much	of	this	dilemma	is	due	to	the	scarcity	of	evidence.	Lack	of	adequate	
evidence	 is	 also	 clear	 as	 shown	 by	 the	 systematic	 review	 carried	 out	 in	 this	
study.	 There	 are	 high	 clinical	 and	 statistical	 heterogeneity	 among	 the	 studies	
included.		
Hence,	 to	 address	 the	 issue,	 a	 randomised	 controlled	 trial	 comparing	 the	 two	
most	commonly	performed	treatments	—IUI	stimulated	with	FSH	versus	IVF	as	
the	first	line	treatment	option	for	unexplained	subfertility—	was	conducted.	207	
couples	 with	 unexplained	 subfertility	 participated.	 They	 were	 randomised	 to	
three	cycles	of	IUI	+	FSH	or	one	cycle	of	IVF.	The	trial	showed	that	there	was	no	
statistical	significant	difference	between	three	cycles	of	IUI	+	FSH	in	comparison	
to	 one	 cycle	 of	 IVF	 in	 terms	 of	 singleton	 live	 birth	 rates.	While	 there	were	 no	
	 87	
differences	in	multiple	pregnancy	rates	between	IUI	and	IVF,	the	OHSS	rate	was	
higher	 for	 IVF.	 It	 is	 interesting	 to	 note	 that	 there	 were	 large	 numbers	 of	
spontaneous	pregnancies	 in	between	 treatment	 cycles.	This	 shows	 the	 relative	
nature	 of	 subfertility	 in	 these	 couples	 and	 that	 an	 expectant	 management	
remains	a	valid	treatment	option	for	them.		
This	 was	 the	 first	 trial	 conducted	 in	 the	 UK	 and	 provides	 a	 head-to-head	
comparison	 between	 the	 two	 most	 commonly	 performed	 treatments.	 The	
pragmatic	nature	of	the	trial	makes	the	results	highly	generalisable.		
Although	unprecedented	support	 from	the	patients	was	received,	as	evident	by	
the	 smooth	 recruitment	 for	 the	 trial,	 it	 was	 not	 smooth	 sailing,	 especially	
towards	 the	 end	 of	 the	 trial.	 As	 the	 NICE	 guideline	 was	 published	 in	 2013	
recommending	 IVF	 as	 the	 only	 treatment	 for	 this	 group	 of	 patients	 after	 two	
years	 of	 trying,	 the	 CCGs	 one	 by	 one	 started	 to	 cease	 their	 funding	 for	 IUI.	
However,	 the	 NICE	 guideline	 was	 not	 based	 on	 robust	 evidence,	 which	 was	
acknowledged	 by	 the	 NICE	 guideline	 development	 group.	 In	 this	 trial,	 only	
couples	who	had	their	IVF	or	IUI	treatment	funded	by	NHS	were	included.	Self-
funded	patients	were	excluded	due	to	lack	of	research	funding.	As	the	funding	for	
IUI	 was	 withdrawn,	 there	 was	 no	 other	 option	 than	 to	 stop	 the	 recruitment	
prematurely.	However,	no	interim	analysis	was	carried	out	and	the	closure	of	the	
trial	 was	 done	 without	 knowledge	 of	 the	 results.	 This	 was	 purely	 for	
administrative	 reasons	 beyond	 the	 investigator’s	 control.	 Since	 the	 intended	
sample	 size	 was	 not	 reached,	 the	 results	 should	 be	 interpreted	 with	 caution.	
Larger	trials	are	warranted.		
A	detailed	health	economics	cost	effective	analysis	was	beyond	the	scope	of	this	








Overall,	 in	 couples	with	a	 female	partner	of	 less	 than	37	years	of	age,	 it	 seems	
logical	 to	offer	expectant	management	 to	 those	 trying	 to	conceive	 for	 less	 than	
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